
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Evidence-based clinical decision support templates for neurological diagnoses">
      
      
      
        <link rel="canonical" href="https://blondarb.github.io/neuro-plans/plans/breakthrough-seizure/">
      
      
        <link rel="prev" href="../new-onset-seizure/">
      
      
        <link rel="next" href="../acute-ischemic-stroke/">
      
      
        
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.7.1">
    
    
      
        <title>Breakthrough Seizure - Neuro Clinical Plans</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.484c7ddc.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.ab4e12ef.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../assets/css/custom.css">
    
    <script>__md_scope=new URL("../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#breakthrough-seizure-known-epilepsy" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="Neuro Clinical Plans" class="md-header__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Neuro Clinical Plans
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Breakthrough Seizure
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a4 4 0 0 0-4 4 4 4 0 0 0 4 4 4 4 0 0 0 4-4 4 4 0 0 0-4-4m0 10a6 6 0 0 1-6-6 6 6 0 0 1 6-6 6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 18c-.89 0-1.74-.2-2.5-.55C11.56 16.5 13 14.42 13 12s-1.44-4.5-3.5-5.45C10.26 6.2 11.11 6 12 6a6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
      <div class="md-header__source">
        <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="Neuro Clinical Plans" class="md-nav__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    Neuro Clinical Plans
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Home
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../clinical/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Interactive Clinical Tool
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--section md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3" checked>
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    Clinical Plans
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Clinical Plans
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Overview
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
    
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3_2" checked>
        
          
          <label class="md-nav__link" for="__nav_3_2" id="__nav_3_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Seizures & Epilepsy
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_2_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3_2">
            <span class="md-nav__icon md-icon"></span>
            
  
    Seizures & Epilepsy
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../status-epilepticus/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Status Epilepticus
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../new-onset-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    New Onset Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
        
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment-protocols" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT PROTOCOLS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendices" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDICES
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_3" >
        
          
          <label class="md-nav__link" for="__nav_3_3" id="__nav_3_3_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Stroke & Vascular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Stroke & Vascular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-ischemic-stroke/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Ischemic Stroke
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../transient-ischemic-attack/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Transient Ischemic Attack
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../intracerebral-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Intracerebral Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../subarachnoid-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Subarachnoid Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_4" >
        
          
          <label class="md-nav__link" for="__nav_3_4" id="__nav_3_4_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuromuscular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../guillain-barre-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Guillain-Barré Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../myasthenia-gravis-crisis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenic Crisis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../myasthenia-gravis-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../neuromuscular-respiratory-failure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular Respiratory Failure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../peripheral-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Peripheral Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_5" >
        
          
          <label class="md-nav__link" for="__nav_3_5" id="__nav_3_5_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    CNS Infections
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_5_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_5">
            <span class="md-nav__icon md-icon"></span>
            
  
    CNS Infections
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../bacterial-meningitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bacterial Meningitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../hsv-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    HSV Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../autoimmune-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_6" >
        
          
          <label class="md-nav__link" for="__nav_3_6" id="__nav_3_6_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Spinal Emergencies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_6_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_6">
            <span class="md-nav__icon md-icon"></span>
            
  
    Spinal Emergencies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-myelopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Myelopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../spinal-cord-compression-malignant/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Spinal Cord Compression (Malignant)
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../cauda-equina-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cauda Equina Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../epidural-abscess/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Epidural Abscess
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_7" >
        
          
          <label class="md-nav__link" for="__nav_3_7" id="__nav_3_7_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuro-Oncology
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_7_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_7">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuro-Oncology
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../brain-metastases/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_8" >
        
          
          <label class="md-nav__link" for="__nav_3_8" id="__nav_3_8_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Critical Care
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_8_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_8">
            <span class="md-nav__icon md-icon"></span>
            
  
    Critical Care
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../elevated-icp-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Elevated ICP Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_9" >
        
          
          <label class="md-nav__link" for="__nav_3_9" id="__nav_3_9_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Demyelinating
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_9_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_9">
            <span class="md-nav__icon md-icon"></span>
            
  
    Demyelinating
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../ms-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_10" >
        
          
          <label class="md-nav__link" for="__nav_3_10" id="__nav_3_10_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Other
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_10_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_10">
            <span class="md-nav__icon md-icon"></span>
            
  
    Other
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../rapidly-progressive-dementia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Rapidly Progressive Dementia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../vertigo-dizziness-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Vertigo / Dizziness
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_4" >
        
          
          <label class="md-nav__link" for="__nav_4" id="__nav_4_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    References
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    References
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/lp-reference/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    LP Reference
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/tracker/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Template Tracker
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment-protocols" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT PROTOCOLS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendices" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDICES
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              
              <article class="md-content__inner md-typeset">
                
                  


  
  


<h1 id="breakthrough-seizure-known-epilepsy">Breakthrough Seizure (Known Epilepsy)<a class="headerlink" href="#breakthrough-seizure-known-epilepsy" title="Permanent link">&para;</a></h1>
<p><strong>VERSION:</strong> 1.0
<strong>CREATED:</strong> January 27, 2026
<strong>STATUS:</strong> Initial build</p>
<hr />
<p><strong>DIAGNOSIS:</strong> Breakthrough Seizure in Known Epilepsy</p>
<p><strong>ICD-10:</strong> G40.909 (Epilepsy, unspecified, not intractable, without status epilepticus), G40.901 (Epilepsy, unspecified, not intractable, with status epilepticus), G40.919 (Epilepsy, unspecified, intractable, without status epilepticus), R56.9 (Unspecified convulsions)</p>
<p><strong>SYNONYMS:</strong> Breakthrough seizure, seizure in known epilepsy, recurrent seizure, uncontrolled seizure, epilepsy exacerbation, seizure on medications, drug-resistant epilepsy, refractory epilepsy, seizure despite treatment</p>
<p><strong>SCOPE:</strong> Evaluation and management of breakthrough seizures in adults with known epilepsy who are on established antiseizure medication (ASM) regimens. Covers identification of precipitants, medication level assessment, adjustment strategies, and evaluation for secondary causes. Excludes new-onset seizure (separate workup), status epilepticus (see SE template), and non-epileptic events (psychogenic non-epileptic seizures).</p>
<hr />
<p><strong>PRIORITY KEY:</strong> STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>
<p>═══════════════════════════════════════════════════════════════
SECTION A: ACTION ITEMS
═══════════════════════════════════════════════════════════════</p>
<h2 id="1-laboratory-workup">1. LABORATORY WORKUP<a class="headerlink" href="#1-laboratory-workup" title="Permanent link">&para;</a></h2>
<h3 id="1a-essentialcore-labs">1A. Essential/Core Labs<a class="headerlink" href="#1a-essentialcore-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiseizure medication (ASM) levels</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td><strong>CRITICAL</strong>: Subtherapeutic levels are #1 cause of breakthrough seizures; check ALL ASMs with available assays</td>
<td>Therapeutic ranges (see Appendix); subtherapeutic = adjust dose or assess adherence</td>
</tr>
<tr>
<td>CBC with differential</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Infection as precipitant; baseline for ASM hematologic effects; thrombocytopenia (valproate)</td>
<td>Normal; leukocytosis → infection workup; low platelets → consider valproate toxicity</td>
</tr>
<tr>
<td>CMP (BMP + LFTs)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Electrolyte abnormalities (hyponatremia common with carbamazepine/oxcarbazepine); renal function (affects ASM dosing); hepatic function (ASM metabolism, toxicity); glucose (hypoglycemia as seizure cause)</td>
<td>Normal; hyponatremia &lt;130 mEq/L can provoke seizures; elevated LFTs → ASM hepatotoxicity</td>
</tr>
<tr>
<td>Blood glucose</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Hypoglycemia is reversible seizure cause; hyperglycemia (DKA) can also cause seizures</td>
<td>70-180 mg/dL; hypoglycemia &lt;60 mg/dL → treat immediately</td>
</tr>
<tr>
<td>Sodium</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Hyponatremia: carbamazepine and oxcarbazepine cause SIADH; &lt;125-130 mEq/L can provoke seizures</td>
<td>135-145 mEq/L; &lt;130 → correct slowly (risk of osmotic demyelination)</td>
</tr>
<tr>
<td>Calcium (ionized)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Hypocalcemia can cause seizures; also check if hypocalcemic tetany suspected</td>
<td>Normal ionized Ca; low → replete</td>
</tr>
<tr>
<td>Magnesium</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Hypomagnesemia lowers seizure threshold; chronic ASM use may deplete Mg</td>
<td>&gt;2.0 mg/dL; low → replete</td>
</tr>
<tr>
<td>Urinalysis</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>UTI is common occult infection that provokes seizures, especially in elderly</td>
<td>Normal; pyuria/bacteriuria → treat UTI</td>
</tr>
<tr>
<td>Urine drug screen (UDS)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Illicit drug use (cocaine, amphetamines) can provoke seizures; drug interactions with ASMs; adherence assessment</td>
<td>Negative; positive → specific drug-related seizure risk assessment</td>
</tr>
<tr>
<td>Alcohol level</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Alcohol withdrawal seizures; intoxication; binge drinking</td>
<td>Negative or low; elevated or history of recent heavy use → alcohol withdrawal protocol</td>
</tr>
<tr>
<td>Pregnancy test (β-hCG)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Pregnancy affects ASM levels (increased clearance, volume distribution); teratogenicity concerns; seizure risk in pregnancy</td>
<td>Document result; if positive → urgent neurology/OB consultation; ASM teratogenicity counseling</td>
</tr>
</tbody>
</table>
<h3 id="1b-extended-workup-second-line">1B. Extended Workup (Second-line)<a class="headerlink" href="#1b-extended-workup-second-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free (unbound) ASM levels</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>For highly protein-bound drugs (phenytoin, valproate) in patients with hypoalbuminemia, renal failure, pregnancy, or polypharmacy; free level is the active fraction</td>
<td>Free phenytoin: 1-2 mcg/mL; free valproate: 5-15 mcg/mL; adjusted interpretation based on clinical context</td>
</tr>
<tr>
<td>Ammonia</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Valproate-induced hyperammonemic encephalopathy (can occur with normal LFTs); confusion/lethargy post-ictal vs. encephalopathy</td>
<td>&lt;35 μmol/L; elevated → valproate toxicity; consider discontinuation</td>
</tr>
<tr>
<td>Lactate</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Post-ictal lactate elevation (typically resolves within 2h); persistent elevation may indicate status epilepticus or alternative cause</td>
<td>Mildly elevated post-ictal (normalizes quickly); persistent elevation concerning</td>
</tr>
<tr>
<td>Prolactin</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Elevated 10-20 min post-seizure (2-3x baseline); helps distinguish epileptic seizure from psychogenic non-epileptic seizure (PNES); must be drawn within 20 min</td>
<td>2-3x baseline within 20 min of convulsive seizure; normal in PNES</td>
</tr>
<tr>
<td>TSH</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Thyroid dysfunction can affect seizure threshold and ASM metabolism</td>
<td>Normal</td>
</tr>
<tr>
<td>Cortisol (AM)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Adrenal insufficiency; chronic ASM use (enzyme inducers) may affect cortisol</td>
<td>Normal</td>
</tr>
<tr>
<td>B12 / Folate</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Phenytoin and carbamazepine can deplete folate; B12 deficiency neuropathy; pregnancy planning</td>
<td>Normal; low → supplement</td>
</tr>
<tr>
<td>Vitamin D (25-OH)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Enzyme-inducing ASMs (phenytoin, carbamazepine, phenobarbital) increase vitamin D metabolism → osteoporosis risk</td>
<td>&gt;30 ng/mL; low → supplement</td>
</tr>
</tbody>
</table>
<h3 id="1c-rarespecialized-refractory-or-atypical">1C. Rare/Specialized (Refractory or Atypical)<a class="headerlink" href="#1c-rarespecialized-refractory-or-atypical" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASM pharmacogenomics (HLA typing)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>HLA-B<em>15:02 (carbamazepine/SJS risk in Asian populations); HLA-A</em>31:01 (carbamazepine hypersensitivity in Europeans); before starting new ASMs</td>
<td>Negative for risk alleles; positive → avoid associated ASM</td>
</tr>
<tr>
<td>Carbamazepine-10,11-epoxide level</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Active metabolite of carbamazepine; may be elevated when total level appears therapeutic (especially with inhibitors like valproate); correlates with toxicity</td>
<td>&lt;9 mcg/mL; elevated → toxicity even with normal carbamazepine level</td>
</tr>
<tr>
<td>Autoimmune encephalitis panel</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>If new seizure semiology, cognitive decline, or refractory seizures in previously controlled patient; autoimmune etiology</td>
<td>Negative; positive → autoimmune encephalitis workup</td>
</tr>
<tr>
<td>CSF analysis</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td>If infection, autoimmune encephalitis, or CNS malignancy suspected as new cause</td>
<td>Normal; abnormal → specific diagnosis</td>
</tr>
<tr>
<td>Genetic epilepsy panel</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>If genetic cause suspected (family history, syndromic features, drug-resistant epilepsy); may guide ASM selection</td>
<td>Specific mutations (SCN1A, SCN2A, KCNQ2, etc.) may inform treatment choices (e.g., avoid sodium channel blockers in Dravet syndrome)</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="2-diagnostic-imaging-studies">2. DIAGNOSTIC IMAGING &amp; STUDIES<a class="headerlink" href="#2-diagnostic-imaging-studies" title="Permanent link">&para;</a></h2>
<h3 id="2a-essentialfirst-line">2A. Essential/First-line<a class="headerlink" href="#2a-essentialfirst-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT head without contrast</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td><strong>NOT routinely needed</strong> for uncomplicated breakthrough seizure in known epilepsy with return to baseline; <strong>INDICATED if:</strong> Head trauma (fall during seizure), prolonged post-ictal state (&gt;30 min), focal neurologic deficit, new seizure semiology, anticoagulation, fever + seizure, first seizure at this facility</td>
<td>Acute hemorrhage; mass lesion; edema; hydrocephalus; prior surgical changes</td>
<td>None (for non-contrast); pregnancy (benefit outweighs minimal risk)</td>
</tr>
<tr>
<td>MRI brain with and without contrast</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td><strong>NOT acutely needed</strong> if stable known epilepsy with unchanged seizures; <strong>INDICATED if:</strong> Change in seizure semiology, increased seizure frequency without clear precipitant, new focal deficit, concern for progressive lesion, presurgical evaluation</td>
<td>Tumor; mesial temporal sclerosis; cortical dysplasia; vascular malformation; new structural cause</td>
<td>MRI-incompatible implants; VNS devices (check MRI compatibility of specific device)</td>
</tr>
<tr>
<td>ECG (12-lead)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Post-ictal arrhythmia; syncope vs. seizure; QTc prolongation (some ASMs); baseline for ASM changes</td>
<td>Normal; arrhythmia may indicate cardiac cause; prolonged QTc (avoid QT-prolonging ASMs)</td>
<td>None</td>
</tr>
</tbody>
</table>
<h3 id="2b-extended">2B. Extended<a class="headerlink" href="#2b-extended" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>EEG (routine/outpatient)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Within 24-48h if possible (higher yield closer to seizure); characterize epileptiform activity; confirm epileptic vs. non-epileptic; guide ASM choice; localization</td>
<td>Epileptiform discharges (spikes, sharp waves); focal vs. generalized; specific epilepsy syndrome features</td>
<td>None</td>
</tr>
<tr>
<td>Continuous EEG (cEEG) monitoring</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td><strong>INDICATED if:</strong> Prolonged or fluctuating alteration of consciousness; concern for nonconvulsive status epilepticus (NCSE); ICU patient with unexplained encephalopathy; frequent seizures</td>
<td>Ictal patterns; NCSE; interictal epileptiform activity; quantify seizure burden</td>
<td>None; resource-dependent</td>
</tr>
<tr>
<td>Ambulatory EEG (outpatient)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Capture typical events if infrequent; home monitoring for 24-72h or longer</td>
<td>Ictal events; interictal discharges; seizure frequency</td>
<td>Patient cooperation required</td>
</tr>
<tr>
<td>Video-EEG monitoring (EMU admission)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Characterize events if diagnostic uncertainty (epileptic vs. PNES); presurgical evaluation; medication taper for surgery</td>
<td>Ictal semiology; EEG correlation; localization for surgery</td>
<td>Requires specialized unit</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Aspiration pneumonia (common post-ictal complication); ETT position if intubated</td>
<td>Infiltrate; aspiration pattern</td>
<td>None</td>
</tr>
</tbody>
</table>
<h3 id="2c-rareadvanced">2C. Rare/Advanced<a class="headerlink" href="#2c-rareadvanced" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI epilepsy protocol</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>High-resolution imaging for epileptogenic lesion identification; 3T preferred; includes thin-cut coronal T2/FLAIR through temporal lobes</td>
<td>Mesial temporal sclerosis; focal cortical dysplasia; cavernous malformation; low-grade tumor</td>
<td>Same as standard MRI</td>
</tr>
<tr>
<td>PET (FDG) or SPECT (ictal/interictal)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Presurgical localization; hypometabolism (interictal PET) or hyperperfusion (ictal SPECT) at seizure focus</td>
<td>Focal hypometabolism (interictal); focal hyperperfusion (ictal)</td>
<td>Radiation exposure; specialized availability</td>
</tr>
<tr>
<td>MEG (magnetoencephalography)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Presurgical localization; dipole source analysis; specialized centers</td>
<td>Source localization complementary to EEG</td>
<td>Limited availability; metal implants</td>
</tr>
<tr>
<td>Neuropsychological testing</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Presurgical evaluation; cognitive baseline; localization (memory lateralization for temporal lobe epilepsy)</td>
<td>Lateralized deficits; cognitive baseline for surgery comparison</td>
<td>Patient cooperation</td>
</tr>
</tbody>
</table>
<h3 id="lumbar-puncture">Lumbar Puncture<a class="headerlink" href="#lumbar-puncture" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>LP — Generally NOT indicated</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td>NOT routinely indicated for uncomplicated breakthrough seizure; <strong>INDICATED if:</strong> Suspected meningitis/encephalitis (fever, meningismus, altered mentation beyond typical post-ictal); suspected autoimmune encephalitis; immunocompromised patient with seizure</td>
<td>Normal in uncomplicated breakthrough; pleocytosis → infection or autoimmune; elevated protein; specific antibodies</td>
<td>Mass lesion with mass effect; coagulopathy</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="3-treatment-protocols">3. TREATMENT PROTOCOLS<a class="headerlink" href="#3-treatment-protocols" title="Permanent link">&para;</a></h2>
<h3 id="3a-acuteemergent-treatment">3A. Acute/Emergent Treatment<a class="headerlink" href="#3a-acuteemergent-treatment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Protocol</th>
<th>Evidence/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benzodiazepine (if actively seizing)</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td><strong>Lorazepam</strong> 0.1 mg/kg IV (max 4 mg), may repeat x1 in 5 min; <strong>OR Midazolam</strong> 10 mg IM (if no IV access); <strong>OR Diazepam</strong> 0.2 mg/kg IV (max 10 mg); <strong>Intranasal midazolam</strong> 5-10 mg if no IV; <strong>Rectal diazepam</strong> 0.2-0.5 mg/kg (home rescue)</td>
<td>First-line for acute seizure termination; lorazepam preferred IV (longer CNS duration); follow status epilepticus protocol if seizure continues &gt;5 min</td>
</tr>
<tr>
<td><strong>Protect patient during seizure</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Clear environment of hazards; DO NOT restrain or put anything in mouth; turn on side (recovery position) when safe; suction secretions; monitor airway; time the seizure</td>
<td>Prevent injury; prepare for airway management if prolonged</td>
</tr>
<tr>
<td><strong>Post-ictal care</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Recovery position; monitor airway (aspiration risk); supplemental O2 if SpO2 &lt;92%; assess for injuries (tongue laceration, shoulder dislocation, vertebral fracture); reassurance; reorientation</td>
<td>Post-ictal period is self-limited (typically 5-30 min); prolonged alteration → consider NCSE, repeat seizure, or alternative diagnosis</td>
</tr>
<tr>
<td><strong>Administer home ASM (if missed)</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>If patient missed doses → give maintenance ASM immediately; if patient does not have medication with them → administer from ED/hospital supply</td>
<td>Non-adherence is most common cause of breakthrough seizure; restoring therapeutic levels is priority</td>
</tr>
<tr>
<td><strong>Loading dose (if significantly subtherapeutic)</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td><strong>Phenytoin/Fosphenytoin:</strong> 15-20 mg PE/kg IV (if level very low); <strong>Valproate:</strong> 20-30 mg/kg IV (if level very low); <strong>Levetiracetam:</strong> 1000-1500 mg IV (if not on levetiracetam — can be added); <strong>Note:</strong> Loading the same drug patient is already taking risks toxicity → use cautiously</td>
<td>For significantly subtherapeutic levels or if need rapid therapeutic concentration; adjust for partial levels</td>
</tr>
<tr>
<td><strong>Treat precipitant</strong></td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td><strong>Infection:</strong> Antibiotics for UTI, pneumonia; <strong>Electrolyte abnormality:</strong> Correct (hyponatremia slowly); <strong>Drug/alcohol withdrawal:</strong> Appropriate protocol; <strong>Sleep deprivation:</strong> Education, sleep hygiene</td>
<td>Treating the precipitant may be more important than adjusting ASMs</td>
</tr>
</tbody>
</table>
<h3 id="3b-asm-adjustment-strategies">3B. ASM Adjustment Strategies<a class="headerlink" href="#3b-asm-adjustment-strategies" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Scenario</th>
<th>Treatment</th>
<th>Protocol</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subtherapeutic level due to non-adherence</strong></td>
<td>Resume current regimen at prescribed doses</td>
<td>Counsel on importance of adherence; identify barriers (cost, side effects, complexity); pill organizer; simplify regimen if possible</td>
<td>Non-adherence is #1 cause; restoring regimen usually sufficient</td>
</tr>
<tr>
<td><strong>Subtherapeutic level at maximum dose</strong></td>
<td>Increase current ASM OR add second ASM</td>
<td>Increase dose if tolerated and therapeutic range allows; OR add complementary ASM (e.g., add levetiracetam to lamotrigine)</td>
<td>Some patients require levels above "therapeutic range" for control</td>
</tr>
<tr>
<td><strong>Therapeutic level but breakthrough seizure</strong></td>
<td>Add second ASM OR optimize current ASM timing</td>
<td>Consider drug-drug interaction reducing efficacy; add ASM with different mechanism; divide doses more frequently for better coverage</td>
<td>Breakthrough at therapeutic levels may require adjunctive therapy</td>
</tr>
<tr>
<td><strong>Subtherapeutic due to drug interaction</strong></td>
<td>Remove interacting drug OR increase ASM dose OR switch ASM</td>
<td>Example: Starting enzyme inducer (rifampin, carbamazepine) reduces lamotrigine level by 50% → double lamotrigine dose</td>
<td>Enzyme inducers and inhibitors significantly affect ASM levels</td>
</tr>
<tr>
<td><strong>Pregnancy with subtherapeutic level</strong></td>
<td>Increase dose with frequent monitoring</td>
<td>Pregnancy increases clearance (especially lamotrigine, levetiracetam); monitor levels monthly; anticipate need for increased doses</td>
<td>Seizure risk to mother and fetus outweighs small ASM risk; maintain control</td>
</tr>
<tr>
<td><strong>New-onset breakthrough in previously controlled epilepsy</strong></td>
<td>Full re-evaluation</td>
<td>Imaging (new structural lesion?); EEG; consider progressive cause (tumor, autoimmune); assess for PNES</td>
<td>Change in control pattern requires investigation for new etiology</td>
</tr>
</tbody>
</table>
<h3 id="3c-specific-asm-adjustments">3C. Specific ASM Adjustments<a class="headerlink" href="#3c-specific-asm-adjustments" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>ASM</th>
<th>Therapeutic Range</th>
<th>Adjustment Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phenytoin</strong></td>
<td>Total: 10-20 mcg/mL; Free: 1-2 mcg/mL</td>
<td>Nonlinear kinetics; small dose changes → large level changes; check free level if hypoalbuminemia, renal failure, pregnancy; adjust dose by 25-50 mg increments</td>
</tr>
<tr>
<td><strong>Carbamazepine</strong></td>
<td>4-12 mcg/mL</td>
<td>Auto-induction over 2-4 weeks (levels drop); check 4 weeks after initiation; also check epoxide level if toxicity suspected</td>
</tr>
<tr>
<td><strong>Valproate</strong></td>
<td>Total: 50-100 mcg/mL; Free: 5-15 mcg/mL</td>
<td>Highly protein-bound; check free level in elderly, hepatic disease, pregnancy; check ammonia if encephalopathy</td>
</tr>
<tr>
<td><strong>Levetiracetam</strong></td>
<td>Not routinely monitored (no established range)</td>
<td>Level: 12-46 mcg/mL often cited; renal dosing required; generally well-tolerated dose increases</td>
</tr>
<tr>
<td><strong>Lamotrigine</strong></td>
<td>3-14 mcg/mL (varies)</td>
<td>Highly affected by enzyme inducers (carbamazepine, phenytoin, oral contraceptives) and inhibitors (valproate); pregnancy increases clearance; slow titration to avoid rash</td>
</tr>
<tr>
<td><strong>Oxcarbazepine</strong></td>
<td>10,11-monohydroxy derivative: 3-35 mcg/mL</td>
<td>Causes hyponatremia (check sodium); less drug interactions than carbamazepine</td>
</tr>
<tr>
<td><strong>Lacosamide</strong></td>
<td>10-20 mcg/mL (emerging data)</td>
<td>Check ECG (PR prolongation); dose-dependent side effects; no major drug interactions</td>
</tr>
<tr>
<td><strong>Topiramate</strong></td>
<td>5-20 mcg/mL (not well-established)</td>
<td>Renal dosing; causes metabolic acidosis, cognitive effects, kidney stones; enzyme inducer reduces OCP efficacy</td>
</tr>
<tr>
<td><strong>Phenobarbital</strong></td>
<td>15-40 mcg/mL</td>
<td>Long half-life (adjust weekly); sedation; enzyme inducer</td>
</tr>
<tr>
<td><strong>Brivaracetam</strong></td>
<td>Not routinely monitored</td>
<td>Similar to levetiracetam but may have fewer behavioral side effects; can substitute directly for levetiracetam</td>
</tr>
<tr>
<td><strong>Clobazam</strong></td>
<td>0.03-0.3 mcg/mL (+ N-desmethylclobazam metabolite)</td>
<td>Benzodiazepine; tolerance may develop; useful adjunct especially in Lennox-Gastaut</td>
</tr>
</tbody>
</table>
<h3 id="3d-non-pharmacologic-considerations">3D. Non-Pharmacologic Considerations<a class="headerlink" href="#3d-non-pharmacologic-considerations" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Intervention</th>
<th>Setting</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Seizure precautions</strong></td>
<td>HOSP/ICU</td>
<td>Padded side rails; suction at bedside; no sharps within reach; fall risk protocol; 1:1 supervision if frequent seizures</td>
</tr>
<tr>
<td><strong>Driving restrictions</strong></td>
<td>OPD/Discharge</td>
<td>State-specific laws; generally 3-12 months seizure-free required; document counseling; patient should NOT drive until cleared</td>
</tr>
<tr>
<td><strong>Activity restrictions</strong></td>
<td>OPD/Discharge</td>
<td>Avoid swimming alone; no heights (ladders, scaffolding); avoid dangerous machinery; bathing vs. showers (supervision if frequent seizures)</td>
</tr>
<tr>
<td><strong>Sleep hygiene</strong></td>
<td>OPD/Discharge</td>
<td>Sleep deprivation is major trigger; regular sleep schedule; 7-8 hours nightly; avoid shift work if possible</td>
</tr>
<tr>
<td><strong>Alcohol / substance avoidance</strong></td>
<td>OPD/Discharge</td>
<td>Alcohol lowers seizure threshold; withdrawal is high risk; cocaine/amphetamines provoke seizures; counsel strongly</td>
</tr>
<tr>
<td><strong>Stress management</strong></td>
<td>OPD/Discharge</td>
<td>Stress/anxiety are common triggers; counseling; mindfulness; adequate support</td>
</tr>
<tr>
<td><strong>VNS (vagus nerve stimulator) check</strong></td>
<td>OPD</td>
<td>If patient has VNS → check device function; consider adjusting parameters; use magnet during seizure if trained</td>
</tr>
<tr>
<td><strong>Ketogenic diet (if on)</strong></td>
<td>OPD</td>
<td>Ensure compliance; check ketosis; dietary counseling</td>
</tr>
<tr>
<td><strong>Epilepsy surgery evaluation</strong></td>
<td>OPD</td>
<td>If drug-resistant epilepsy (failure of 2 appropriate ASMs at adequate doses) → refer for surgical evaluation</td>
</tr>
</tbody>
</table>
<h3 id="3e-medications-to-avoid-or-use-with-caution">3E. Medications to AVOID or Use with Caution<a class="headerlink" href="#3e-medications-to-avoid-or-use-with-caution" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Medication</th>
<th>Risk</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tramadol</strong></td>
<td>Lowers seizure threshold significantly</td>
<td>Avoid in epilepsy; use alternative analgesics</td>
</tr>
<tr>
<td><strong>Meperidine (Demerol)</strong></td>
<td>Lowers seizure threshold (normeperidine metabolite)</td>
<td>Avoid; use other opioids</td>
</tr>
<tr>
<td><strong>Bupropion</strong></td>
<td>Dose-dependent seizure risk (especially &gt;450 mg/day)</td>
<td>Avoid or use cautiously at low doses if essential for depression</td>
</tr>
<tr>
<td><strong>Clozapine</strong></td>
<td>High seizure risk (dose-dependent)</td>
<td>Avoid if possible; if used, prophylactic ASM often recommended</td>
</tr>
<tr>
<td><strong>Fluoroquinolones</strong></td>
<td>May lower seizure threshold; GABA antagonism</td>
<td>Use with caution; consider alternative antibiotics</td>
</tr>
<tr>
<td><strong>Carbapenems (imipenem &gt; meropenem)</strong></td>
<td>Lower seizure threshold; reduce valproate levels significantly</td>
<td>Imipenem: avoid if possible; meropenem: use with caution; monitor valproate level</td>
</tr>
<tr>
<td><strong>Isoniazid</strong></td>
<td>Pyridoxine depletion → seizures; inhibits phenytoin metabolism</td>
<td>Give prophylactic pyridoxine; monitor phenytoin level</td>
</tr>
<tr>
<td><strong>Theophylline / Aminophylline</strong></td>
<td>Lowers seizure threshold</td>
<td>Use cautiously; monitor levels</td>
</tr>
<tr>
<td><strong>Stimulants (amphetamines, methylphenidate)</strong></td>
<td>May lower seizure threshold</td>
<td>Use cautiously if needed for ADHD; generally well-tolerated in controlled epilepsy but monitor</td>
</tr>
<tr>
<td><strong>Alcohol (acute intoxication and withdrawal)</strong></td>
<td>Intoxication and withdrawal both increase seizure risk</td>
<td>Counsel on avoidance</td>
</tr>
<tr>
<td><strong>Illicit drugs (cocaine, amphetamines, synthetic cathinones)</strong></td>
<td>Directly provoke seizures</td>
<td>Counsel on avoidance; drug screen</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="4-other-recommendations">4. OTHER RECOMMENDATIONS<a class="headerlink" href="#4-other-recommendations" title="Permanent link">&para;</a></h2>
<h3 id="4a-essential">4A. Essential<a class="headerlink" href="#4a-essential" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurology consultation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>For medication adjustments, change in seizure pattern, refractory seizures, presurgical evaluation consideration</td>
</tr>
<tr>
<td>ASM level check</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>All ASMs with available assays; interpret in clinical context; free levels for protein-bound drugs</td>
</tr>
<tr>
<td>Adherence assessment</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Ask directly about missed doses; identify barriers (cost, side effects, complexity, depression); pill counts if available; pharmacy refill records</td>
</tr>
<tr>
<td>Precipitant identification</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Infection (UTI most common); sleep deprivation; alcohol; medication changes; stress; menstrual cycle (catamenial epilepsy)</td>
</tr>
<tr>
<td>Injury assessment</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Tongue laceration; posterior shoulder dislocation (classic); vertebral compression fracture; head trauma (if fall)</td>
</tr>
<tr>
<td>Safety counseling</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Driving restrictions (document!); activity limitations; seizure first aid for family; MedicAlert bracelet; rescue medication prescription (rectal diazepam or intranasal midazolam)</td>
</tr>
<tr>
<td>Return to baseline confirmation</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Document return to neurologic baseline; if not returning → consider ongoing seizures (NCSE), structural lesion, metabolic cause</td>
</tr>
</tbody>
</table>
<h3 id="4b-extended">4B. Extended<a class="headerlink" href="#4b-extended" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>EEG</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>If change in seizure pattern, prolonged post-ictal state, concern for NCSE, or to characterize epileptiform activity</td>
</tr>
<tr>
<td>Imaging</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>MRI if change in seizure semiology, new focal findings, or suspicion of progressive lesion; CT acutely if trauma, anticoagulation, or prolonged altered mental status</td>
</tr>
<tr>
<td>Pharmacy consultation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Drug interaction review; adherence strategies; cost-effective alternatives; patient education on ASMs</td>
</tr>
<tr>
<td>Social work</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Insurance/cost barriers to medication; disability resources; driving/employment impact; support services</td>
</tr>
<tr>
<td>Psychology / Psychiatry</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Depression (common comorbidity; some ASMs worsen depression); anxiety; PNES if suspected; coping strategies</td>
</tr>
<tr>
<td>Epilepsy nurse educator</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Self-management education; seizure diary; lifestyle modifications; medication management; rescue medication training</td>
</tr>
<tr>
<td>Women's health counseling</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Contraception (enzyme-inducing ASMs reduce OCP efficacy); pregnancy planning (folic acid, ASM optimization); teratogenicity counseling</td>
</tr>
</tbody>
</table>
<h3 id="4c-atypicalrefractory">4C. Atypical/Refractory<a class="headerlink" href="#4c-atypicalrefractory" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy surgery evaluation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Drug-resistant epilepsy (failed ≥2 appropriate ASMs); refer to comprehensive epilepsy center for surgical workup (video-EEG, MRI epilepsy protocol, neuropsych, PET, etc.)</td>
</tr>
<tr>
<td>VNS / RNS / DBS evaluation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Neuromodulation for drug-resistant epilepsy not surgical candidates; VNS (vagus nerve stimulator); RNS (responsive neurostimulation); DBS (deep brain stimulation)</td>
</tr>
<tr>
<td>Ketogenic diet referral</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Dietary therapy for drug-resistant epilepsy; especially effective in certain epilepsies (Dravet, GLUT1 deficiency); requires dietitian supervision</td>
</tr>
<tr>
<td>PNES evaluation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If clinical features suggest psychogenic non-epileptic seizures (variable semiology, prolonged events, lack of post-ictal state, eyes closed, pelvic thrusting, ictal crying, preserved awareness with bilateral movements); video-EEG confirmation; psychology/psychiatry referral</td>
</tr>
<tr>
<td>Autoimmune epilepsy workup</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If new-onset refractory seizures, cognitive decline, or change in previously controlled epilepsy → autoimmune antibody panel; LP; MRI; consider immunotherapy trial</td>
</tr>
<tr>
<td>Genetic testing</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If suspected genetic epilepsy; may inform ASM selection (e.g., avoid sodium channel blockers in SCN1A/Dravet; valproate effective in SCN2A); family counseling</td>
</tr>
</tbody>
</table>
<hr />
<p>═══════════════════════════════════════════════════════════════
SECTION B: SUPPORTING INFORMATION
═══════════════════════════════════════════════════════════════</p>
<h2 id="5-differential-diagnosis">5. DIFFERENTIAL DIAGNOSIS<a class="headerlink" href="#5-differential-diagnosis" title="Permanent link">&para;</a></h2>
<h3 id="differential-for-breakthrough-seizure">Differential for "Breakthrough Seizure"<a class="headerlink" href="#differential-for-breakthrough-seizure" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Key Distinguishing Features</th>
<th>Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>True breakthrough seizure (epileptic)</strong></td>
<td>Typical semiology for patient; post-ictal state; EEG correlation; identifiable precipitant or subtherapeutic level</td>
<td>ASM levels; EEG; precipitant search</td>
</tr>
<tr>
<td><strong>Psychogenic non-epileptic seizure (PNES)</strong></td>
<td>Variable semiology; prolonged duration (&gt;2 min); preserved awareness with bilateral movements; eyes closed; pelvic thrusting; ictal crying; side-to-side head movements; no post-ictal confusion (or prolonged pseudo-post-ictal); normal prolactin; normal EEG during event</td>
<td>Video-EEG (gold standard); prolactin (not elevated); clinical features; psychology evaluation</td>
</tr>
<tr>
<td><strong>Syncope (convulsive)</strong></td>
<td>Triggered by standing, hot environment, vagal stimulus; brief LOC (&lt;1 min); myoclonic jerks are common during syncope (not true seizure); rapid recovery; pale before event</td>
<td>ECG; orthostatics; tilt table test; echocardiogram; cardiac history</td>
</tr>
<tr>
<td><strong>Cardiac arrhythmia</strong></td>
<td>Sudden LOC without warning or with palpitations; rapid recovery; history of cardiac disease</td>
<td>ECG; Holter/event monitor; echocardiogram; electrophysiology study</td>
</tr>
<tr>
<td><strong>Toxic/metabolic</strong></td>
<td>Hypoglycemia; hyponatremia; hypocalcemia; uremia; hepatic encephalopathy; drug intoxication/withdrawal</td>
<td>Glucose; electrolytes; renal/hepatic function; drug screen; specific toxin levels</td>
</tr>
<tr>
<td><strong>Transient ischemic attack (TIA)</strong></td>
<td>Negative symptoms (weakness, numbness, aphasia) vs. positive symptoms (convulsion); typically no LOC; vascular risk factors</td>
<td>MRI with DWI; MRA; vascular risk factor assessment</td>
</tr>
<tr>
<td><strong>Sleep disorders</strong></td>
<td>REM sleep behavior disorder; parasomnias; cataplexy (narcolepsy)</td>
<td>Sleep history; PSG; MSL</td>
</tr>
<tr>
<td><strong>Movement disorders</strong></td>
<td>Dystonia; chorea; myoclonus (non-epileptic); paroxysmal dyskinesia</td>
<td>Preserved awareness; stereotyped movements; neurologic exam; movement disorder evaluation</td>
</tr>
<tr>
<td><strong>Migraine with aura</strong></td>
<td>Visual, sensory, or motor aura preceding headache; duration 20-60 min; no LOC</td>
<td>Headache history; migraine features; may have EEG abnormalities but distinct from seizure</td>
</tr>
</tbody>
</table>
<h3 id="common-precipitants-of-breakthrough-seizures">Common Precipitants of Breakthrough Seizures<a class="headerlink" href="#common-precipitants-of-breakthrough-seizures" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Precipitant</th>
<th>Mechanism</th>
<th>Evaluation/Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-adherence / missed doses</strong></td>
<td>Subtherapeutic ASM levels</td>
<td>Ask directly; check levels; pharmacy refill records; address barriers</td>
</tr>
<tr>
<td><strong>Sleep deprivation</strong></td>
<td>Lowers seizure threshold significantly</td>
<td>Sleep hygiene counseling; regular schedule; treat sleep disorders</td>
</tr>
<tr>
<td><strong>Infection (especially UTI)</strong></td>
<td>Fever lowers seizure threshold; metabolic stress</td>
<td>UA/culture; CXR; treat infection</td>
</tr>
<tr>
<td><strong>Alcohol use / withdrawal</strong></td>
<td>Both intoxication and withdrawal provoke seizures</td>
<td>Alcohol level; history; withdrawal prophylaxis</td>
</tr>
<tr>
<td><strong>Medication changes</strong></td>
<td>Drug interactions; started medication that lowers threshold</td>
<td>Medication reconciliation; check levels; review interactions</td>
</tr>
<tr>
<td><strong>Stress / anxiety</strong></td>
<td>Hyperexcitability</td>
<td>Stress management; counseling; anxiolytics if appropriate</td>
</tr>
<tr>
<td><strong>Menstrual cycle (catamenial epilepsy)</strong></td>
<td>Perimenstrual or periovulatory clustering</td>
<td>Seizure diary correlation; hormonal treatment; increase ASM perimenstrually</td>
</tr>
<tr>
<td><strong>Electrolyte abnormalities</strong></td>
<td>Hyponatremia (carbamazepine, oxcarbazepine); hypocalcemia; hypomagnesemia</td>
<td>Electrolyte panel; correct abnormality</td>
</tr>
<tr>
<td><strong>Illicit drugs</strong></td>
<td>Cocaine, amphetamines lower seizure threshold</td>
<td>Drug screen; counseling</td>
</tr>
<tr>
<td><strong>Flashing lights / photosensitivity</strong></td>
<td>Photic stimulation triggers seizures in photosensitive epilepsy</td>
<td>EEG with photic stimulation; avoid triggers; blue-tinted lenses</td>
</tr>
</tbody>
</table>
<h3 id="red-flags-suggesting-alternative-diagnosis">Red Flags Suggesting Alternative Diagnosis<a class="headerlink" href="#red-flags-suggesting-alternative-diagnosis" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Red Flag</th>
<th>Concern</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>New focal neurologic deficit</td>
<td>New structural lesion (tumor, stroke, hemorrhage)</td>
<td>STAT imaging (CT then MRI)</td>
</tr>
<tr>
<td>Prolonged post-ictal state (&gt;30 min)</td>
<td>Status epilepticus; NCSE; structural lesion; metabolic cause; postictal paralysis (Todd's)</td>
<td>Continuous EEG; imaging; extended metabolic workup</td>
</tr>
<tr>
<td>Fever with seizure</td>
<td>Meningitis/encephalitis; febrile seizure in adult is concerning</td>
<td>LP if meningitis suspected; imaging; antibiotics/antivirals empirically if indicated</td>
</tr>
<tr>
<td>Change in seizure semiology</td>
<td>New epileptogenic lesion; different seizure type; PNES</td>
<td>EEG; MRI; video-EEG if needed</td>
</tr>
<tr>
<td>No return to baseline</td>
<td>Ongoing NCSE; structural lesion; metabolic encephalopathy</td>
<td>Continuous EEG; imaging; metabolic workup</td>
</tr>
<tr>
<td>First seizure at this facility</td>
<td>May not be known epilepsy; needs full new-onset seizure workup</td>
<td>Full workup unless confirmed prior epilepsy</td>
</tr>
<tr>
<td>Eyes closed during "seizure"</td>
<td>PNES (epileptic seizures typically have eyes open)</td>
<td>Video-EEG; psychology referral</td>
</tr>
<tr>
<td>Very prolonged event (&gt;5-10 min)</td>
<td>Status epilepticus; PNES (epileptic seizures typically &lt;2-3 min)</td>
<td>Treat as SE if epileptic; video-EEG for characterization</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-monitoring-parameters">6. MONITORING PARAMETERS<a class="headerlink" href="#6-monitoring-parameters" title="Permanent link">&para;</a></h2>
<h3 id="ed-acute-phase">ED / Acute Phase<a class="headerlink" href="#ed-acute-phase" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental status (return to baseline)</td>
<td>q15 min until resolved; q1h thereafter</td>
<td>Return to baseline within 30-60 min</td>
<td>Prolonged: consider NCSE → EEG; imaging; extended evaluation</td>
</tr>
<tr>
<td>Vital signs</td>
<td>q15-30 min initially; q1h once stable</td>
<td>HR 60-100; BP &lt;180/110; SpO2 &gt;94%; Temp &lt;38°C</td>
<td>Manage accordingly; fever → infection workup</td>
</tr>
<tr>
<td>Seizure recurrence</td>
<td>Continuous observation</td>
<td>No further seizures</td>
<td>Repeat seizure: give benzodiazepine; consider additional ASM load; SE protocol if &gt;5 min</td>
</tr>
<tr>
<td>Airway / Respiratory status</td>
<td>Continuous; q15 min</td>
<td>Patent airway; no aspiration; adequate ventilation</td>
<td>Position; suction; O2 if needed; intubation if compromised</td>
</tr>
<tr>
<td>Blood glucose</td>
<td>Check immediately; repeat if symptomatic</td>
<td>70-180 mg/dL</td>
<td>Hypoglycemia: D50W IV</td>
</tr>
<tr>
<td>Cardiac rhythm</td>
<td>Continuous telemetry</td>
<td>Normal sinus; no arrhythmia</td>
<td>Treat arrhythmia; cardiology if indicated</td>
</tr>
</tbody>
</table>
<h3 id="inpatient-monitoring">Inpatient Monitoring<a class="headerlink" href="#inpatient-monitoring" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASM level (repeat)</td>
<td>24-48h after dose adjustment</td>
<td>Therapeutic (per drug)</td>
<td>Adjust dose</td>
</tr>
<tr>
<td>Sodium (if on carbamazepine/oxcarbazepine)</td>
<td>Daily during hospitalization</td>
<td>&gt;130 mEq/L</td>
<td>Fluid restriction; consider ASM change if persistent hyponatremia</td>
</tr>
<tr>
<td>LFTs (if concern for toxicity)</td>
<td>Q2-3 days if abnormal</td>
<td>AST/ALT &lt;3x ULN</td>
<td>If elevated: consider ASM hepatotoxicity; may need to discontinue</td>
</tr>
<tr>
<td>Ammonia (if on valproate with altered mental status)</td>
<td>With any confusion/lethargy</td>
<td>&lt;35 μmol/L</td>
<td>Elevated: consider discontinuing valproate; L-carnitine supplementation</td>
</tr>
<tr>
<td>Seizure diary</td>
<td>Continuous</td>
<td>Document all events</td>
<td>Assess frequency and response to treatment</td>
</tr>
<tr>
<td>Neurologic exam</td>
<td>Daily</td>
<td>Stable; no new deficits</td>
<td>New deficits: imaging</td>
</tr>
</tbody>
</table>
<h3 id="outpatient-monitoring">Outpatient Monitoring<a class="headerlink" href="#outpatient-monitoring" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASM levels</td>
<td>2-4 weeks after dose change; then q6-12 months or PRN</td>
<td>Therapeutic</td>
<td>Adjust dose</td>
</tr>
<tr>
<td>CBC, CMP</td>
<td>Q6-12 months or per ASM-specific monitoring</td>
<td>Normal</td>
<td>ASM-specific toxicity management</td>
</tr>
<tr>
<td>Bone density (DEXA)</td>
<td>Baseline and q2-5 years if on enzyme-inducing ASMs</td>
<td>T-score &gt;-2.5</td>
<td>Vitamin D, calcium, bisphosphonates if needed</td>
</tr>
<tr>
<td>Seizure frequency</td>
<td>Seizure diary; each visit</td>
<td>Reduced or seizure-free</td>
<td>Adjust ASMs; consider surgery evaluation if drug-resistant</td>
</tr>
<tr>
<td>Side effects</td>
<td>Each visit</td>
<td>Tolerable; no limiting effects</td>
<td>Dose adjustment; consider alternative ASM</td>
</tr>
<tr>
<td>Mood / Cognition</td>
<td>Each visit</td>
<td>No depression; stable cognition</td>
<td>Depression treatment; ASM adjustment if cognitive effects</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="7-disposition-criteria">7. DISPOSITION CRITERIA<a class="headerlink" href="#7-disposition-criteria" title="Permanent link">&para;</a></h2>
<h3 id="admission-criteria">Admission Criteria<a class="headerlink" href="#admission-criteria" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Level of Care</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICU</td>
<td>Status epilepticus; cluster seizures requiring continuous infusion; severe injuries; need for continuous EEG monitoring; airway compromise; hemodynamic instability</td>
</tr>
<tr>
<td>General floor / Observation</td>
<td>Prolonged post-ictal state; multiple seizures in ED; significantly subtherapeutic levels requiring monitoring during adjustment; uncertain diagnosis; new focal deficit; complicating medical illness</td>
</tr>
<tr>
<td>Discharge home</td>
<td>Single uncomplicated breakthrough seizure; returned to baseline; identifiable/correctable precipitant; therapeutic or corrected ASM level; no injuries requiring admission; safe home environment; reliable follow-up</td>
</tr>
</tbody>
</table>
<h3 id="discharge-criteria">Discharge Criteria<a class="headerlink" href="#discharge-criteria" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Criterion</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return to baseline</td>
<td>Normal mental status and neurologic exam matching patient's baseline</td>
</tr>
<tr>
<td>No ongoing seizure activity</td>
<td>Seizure-free since treatment/observation; no concern for subclinical seizures</td>
</tr>
<tr>
<td>Precipitant addressed</td>
<td>Infection treated; missed doses restored; electrolytes corrected; adherence barriers addressed</td>
</tr>
<tr>
<td>ASM plan established</td>
<td>Levels checked; dose adjustments made if indicated; supply of medications ensured</td>
</tr>
<tr>
<td>Safety counseling completed</td>
<td>Driving restrictions documented; activity precautions; seizure first aid for caregivers; when to return</td>
</tr>
<tr>
<td>Follow-up arranged</td>
<td>Neurology follow-up within 1-4 weeks; PCP as needed; EEG scheduled if indicated</td>
</tr>
<tr>
<td>Rescue medication prescribed</td>
<td>Rectal diazepam or intranasal midazolam prescription if appropriate (cluster seizures, prolonged seizures)</td>
</tr>
</tbody>
</table>
<h3 id="discharge-checklist">Discharge Checklist<a class="headerlink" href="#discharge-checklist" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Item</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASM prescriptions</td>
<td>Ensure supply of all ASMs; no gaps in medication</td>
</tr>
<tr>
<td>ASM instructions</td>
<td>Dose, frequency, timing; what to do if dose missed; common side effects</td>
</tr>
<tr>
<td>Driving restrictions</td>
<td>Document state-specific requirement (typically 3-12 months seizure-free); document counseling</td>
</tr>
<tr>
<td>Activity restrictions</td>
<td>No swimming alone; no heights; supervision during bathing if frequent seizures; work restrictions if applicable</td>
</tr>
<tr>
<td>Rescue medication</td>
<td>Prescription and training for rectal diazepam or intranasal midazolam</td>
</tr>
<tr>
<td>Seizure first aid</td>
<td>Education for patient and family; recovery position; when to call 911</td>
</tr>
<tr>
<td>When to return</td>
<td>Return for: repeat seizure, prolonged seizure, status epilepticus, new symptoms, fever with seizure, head injury</td>
</tr>
<tr>
<td>Follow-up</td>
<td>Neurology appointment; EEG if scheduled; PCP follow-up</td>
</tr>
<tr>
<td>MedicAlert</td>
<td>Encourage bracelet/necklace for epilepsy identification</td>
</tr>
<tr>
<td>Seizure diary</td>
<td>Provide or recommend app; track seizures, ASMs, triggers</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="8-evidence-references">8. EVIDENCE &amp; REFERENCES<a class="headerlink" href="#8-evidence-references" title="Permanent link">&para;</a></h2>
<h3 id="key-guidelines">Key Guidelines<a class="headerlink" href="#key-guidelines" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Guideline</th>
<th>Source</th>
<th>Year</th>
<th>Key Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practice Guideline Update: Efficacy and Tolerability of ASMs</td>
<td>AAN</td>
<td>2018</td>
<td>Levetiracetam, lamotrigine, oxcarbazepine, topiramate established for monotherapy; choose based on seizure type, side effect profile, comorbidities</td>
</tr>
<tr>
<td>Management of Adult Epilepsy</td>
<td>AES/ILAE</td>
<td>Ongoing updates</td>
<td>Drug-resistant epilepsy defined as failure of 2 appropriate ASMs at adequate doses; refer for surgery evaluation; multidisciplinary care</td>
</tr>
<tr>
<td>Epilepsy in Women</td>
<td>AAN</td>
<td>2009/Updates</td>
<td>Folic acid 0.4-4 mg daily for all women of childbearing potential; avoid valproate in pregnancy if possible; lamotrigine and levetiracetam generally preferred</td>
</tr>
<tr>
<td>SUDEP Prevention</td>
<td>AAN</td>
<td>2017</td>
<td>Counsel on sudden unexpected death in epilepsy; nocturnal supervision reduces risk; seizure control reduces risk</td>
</tr>
</tbody>
</table>
<h3 id="landmark-studies">Landmark Studies<a class="headerlink" href="#landmark-studies" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Finding</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kwan &amp; Brodie (2000)</td>
<td>47% of newly diagnosed epilepsy patients became seizure-free on first ASM; 13% on second; 4% on third; after failure of 2 appropriate ASMs, chance of seizure freedom with additional ASMs is &lt;5%</td>
<td>Defined drug-resistant epilepsy; established rationale for early surgery referral</td>
</tr>
<tr>
<td>SANAD I &amp; II (2007, 2021)</td>
<td>Lamotrigine best for focal epilepsy; valproate best for generalized/unclassified (but teratogenic); levetiracetam non-inferior to lamotrigine for focal</td>
<td>Guide first-line ASM selection by seizure type</td>
</tr>
<tr>
<td>Standard and New Antiepileptic Drugs (SNAED) Trial</td>
<td>Levetiracetam and zonisamide non-inferior to lamotrigine for focal epilepsy</td>
<td>Expanded first-line options</td>
</tr>
<tr>
<td>Early Randomized Surgical Epilepsy Trial (ERSET, 2012)</td>
<td>Early surgery superior to continued medical therapy for drug-resistant temporal lobe epilepsy; 73% vs. 0% seizure-free at 2 years</td>
<td>Surgery is highly effective; early referral improves outcomes</td>
</tr>
<tr>
<td>SUDEP Risk Factors</td>
<td>Convulsive seizures, especially nocturnal; living alone; poor seizure control</td>
<td>Counsel patients; nocturnal monitoring devices; optimize seizure control</td>
</tr>
</tbody>
</table>
<h3 id="asm-therapeutic-ranges-reference">ASM Therapeutic Ranges (Reference)<a class="headerlink" href="#asm-therapeutic-ranges-reference" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>ASM</th>
<th>Total Level</th>
<th>Free Level</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin</td>
<td>10-20 mcg/mL</td>
<td>1-2 mcg/mL</td>
<td>Free level essential if hypoalbuminemia, renal failure, pregnancy; nonlinear kinetics</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>4-12 mcg/mL</td>
<td>N/A</td>
<td>Check epoxide if toxicity; auto-induction</td>
</tr>
<tr>
<td>Valproate</td>
<td>50-100 mcg/mL</td>
<td>5-15 mcg/mL</td>
<td>Free level in pregnancy, elderly, hepatic disease; check ammonia if encephalopathy</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>15-40 mcg/mL</td>
<td>N/A</td>
<td>Long half-life; steady-state takes weeks</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>12-46 mcg/mL (suggested)</td>
<td>N/A</td>
<td>Not routinely monitored; wide therapeutic range; renal dosing</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>3-14 mcg/mL (varies)</td>
<td>N/A</td>
<td>Highly variable; affected by estrogen, enzyme inducers/inhibitors</td>
</tr>
<tr>
<td>Oxcarbazepine (MHD)</td>
<td>3-35 mcg/mL</td>
<td>N/A</td>
<td>MHD is active metabolite; monitor sodium</td>
</tr>
<tr>
<td>Topiramate</td>
<td>5-20 mcg/mL (suggested)</td>
<td>N/A</td>
<td>Not routinely monitored</td>
</tr>
<tr>
<td>Lacosamide</td>
<td>10-20 mcg/mL (emerging)</td>
<td>N/A</td>
<td>Check ECG for PR prolongation</td>
</tr>
<tr>
<td>Clobazam</td>
<td>0.03-0.3 mcg/mL</td>
<td>N/A</td>
<td>Also measure N-desmethylclobazam metabolite</td>
</tr>
<tr>
<td>Brivaracetam</td>
<td>Not established</td>
<td>N/A</td>
<td>Similar to levetiracetam; not routinely monitored</td>
</tr>
<tr>
<td>Perampanel</td>
<td>Not established</td>
<td>N/A</td>
<td>Long half-life; steady-state takes weeks</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendices">APPENDICES<a class="headerlink" href="#appendices" title="Permanent link">&para;</a></h2>
<h3 id="appendix-a-breakthrough-seizure-evaluation-algorithm">Appendix A: Breakthrough Seizure Evaluation Algorithm<a class="headerlink" href="#appendix-a-breakthrough-seizure-evaluation-algorithm" title="Permanent link">&para;</a></h3>
<div class="highlight"><pre><span></span><code>BREAKTHROUGH SEIZURE IN KNOWN EPILEPSY
                │
    IMMEDIATE MANAGEMENT (if still seizing):
    • Benzodiazepine per protocol
    • Protect patient; do not restrain
    • Time seizure; SE protocol if &gt;5 min
                │
    POST-ICTAL ASSESSMENT:
    • Return to baseline? (typically 5-30 min)
    • Injury assessment
    • Vital signs
                │
    NOT RETURNING TO BASELINE (&gt;30-60 min)?
         │
    YES → Consider:
         • Ongoing NCSE (continuous EEG)
         • Structural lesion (CT/MRI)
         • Metabolic cause
         • Prolonged post-ictal (can be &gt;1h in some patients)
                │
    RETURNED TO BASELINE:
                │
    EVALUATE PRECIPITANT:
    • Non-adherence? (ask directly; levels)
    • Infection? (UTI, pneumonia)
    • Sleep deprivation?
    • Alcohol/drugs?
    • Medication change?
    • Menstrual cycle?
    • Stress?
    • Electrolyte abnormality?
                │
    CHECK ASM LEVELS:
    • Subtherapeutic → Restore/adjust doses
    • Therapeutic → Consider adding ASM or
                    evaluate for change in epilepsy
                │
    IMAGING (NOT routinely needed if):
    • Typical seizure for this patient
    • Returned to baseline
    • No trauma, no new focal signs
    │
    CONSIDER IMAGING IF:
    • New seizure semiology
    • New focal deficit
    • Prolonged post-ictal
    • Head trauma
    • Anticoagulation
    • Immunocompromised
                │
    DISPOSITION:
    • Discharge if: single seizure, baseline, precipitant addressed,
      ASM plan, safe environment, follow-up
    • Admit if: multiple seizures, prolonged post-ictal,
      uncertain diagnosis, injuries, unsafe home
</code></pre></div>
<h3 id="appendix-b-common-drug-interactions-affecting-asm-levels">Appendix B: Common Drug Interactions Affecting ASM Levels<a class="headerlink" href="#appendix-b-common-drug-interactions-affecting-asm-levels" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Interacting Drug</th>
<th>Effect on ASM</th>
<th>Affected ASMs</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Enzyme Inducers</strong> (rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort)</td>
<td>↓ ASM levels</td>
<td>Lamotrigine (↓50%), valproate, topiramate, levetiracetam (mild), clobazam, perampanel</td>
<td>Increase ASM dose; monitor levels</td>
</tr>
<tr>
<td><strong>Enzyme Inhibitors</strong> (valproate, fluoxetine, erythromycin)</td>
<td>↑ ASM levels</td>
<td>Lamotrigine (valproate doubles level), carbamazepine, phenobarbital, phenytoin</td>
<td>Decrease ASM dose; lamotrigine titration much slower when adding to valproate</td>
</tr>
<tr>
<td><strong>Oral Contraceptives</strong> (estrogen)</td>
<td>↓ Lamotrigine levels</td>
<td>Lamotrigine (↓50%)</td>
<td>Increase lamotrigine dose; may need to decrease during pill-free week</td>
</tr>
<tr>
<td><strong>Carbapenems</strong> (imipenem, meropenem)</td>
<td>↓ Valproate levels dramatically</td>
<td>Valproate (↓60-90%)</td>
<td>Avoid combination if possible; if used, significantly increase valproate or use alternative ASM</td>
</tr>
<tr>
<td><strong>Antacids</strong></td>
<td>↓ Absorption of some ASMs</td>
<td>Gabapentin, phenytoin</td>
<td>Separate administration by 2 hours</td>
</tr>
<tr>
<td><strong>Protein-binding displacement</strong></td>
<td>↑ Free ASM fraction</td>
<td>Phenytoin, valproate (with aspirin, warfarin, other highly bound drugs)</td>
<td>Check free levels</td>
</tr>
</tbody>
</table>
<h3 id="appendix-c-asm-selection-by-seizure-type">Appendix C: ASM Selection by Seizure Type<a class="headerlink" href="#appendix-c-asm-selection-by-seizure-type" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Seizure Type</th>
<th>First-Line Options</th>
<th>Avoid</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Focal (aware or impaired awareness)</strong></td>
<td>Lamotrigine, levetiracetam, oxcarbazepine, carbamazepine</td>
<td>Ethosuximide (not effective)</td>
</tr>
<tr>
<td><strong>Focal to bilateral tonic-clonic</strong></td>
<td>Same as focal</td>
<td>Same as focal</td>
</tr>
<tr>
<td><strong>Generalized tonic-clonic</strong></td>
<td>Valproate (if not woman of childbearing potential), lamotrigine, levetiracetam</td>
<td>Carbamazepine, oxcarbazepine, phenytoin (may worsen)</td>
</tr>
<tr>
<td><strong>Absence (typical)</strong></td>
<td>Ethosuximide (first-line for absence only), valproate, lamotrigine</td>
<td>Carbamazepine, oxcarbazepine, phenytoin (can worsen)</td>
</tr>
<tr>
<td><strong>Myoclonic</strong></td>
<td>Valproate, levetiracetam, clonazepam</td>
<td>Carbamazepine, oxcarbazepine, phenytoin, gabapentin (can worsen)</td>
</tr>
<tr>
<td><strong>Juvenile myoclonic epilepsy (JME)</strong></td>
<td>Valproate (most effective but avoid in women), lamotrigine (may worsen myoclonus), levetiracetam</td>
<td>Carbamazepine, oxcarbazepine, phenytoin</td>
</tr>
<tr>
<td><strong>Lennox-Gastaut syndrome</strong></td>
<td>Lamotrigine, valproate, clobazam, rufinamide, felbamate, cannabidiol</td>
<td>N/A (polytherapy usually required)</td>
</tr>
<tr>
<td><strong>Dravet syndrome (SCN1A)</strong></td>
<td>Valproate, clobazam, stiripentol, cannabidiol, fenfluramine</td>
<td><strong>AVOID sodium channel blockers</strong> (carbamazepine, oxcarbazepine, phenytoin, lamotrigine) — can worsen seizures</td>
</tr>
</tbody>
</table>
<h3 id="appendix-d-special-populations">Appendix D: Special Populations<a class="headerlink" href="#appendix-d-special-populations" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Population</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregnancy</strong></td>
<td>Folic acid 0.4-4 mg daily (start preconception); avoid valproate if possible (highest teratogenicity); lamotrigine and levetiracetam generally preferred; levels drop in pregnancy (especially lamotrigine) — monitor monthly and increase doses; valproate level may be falsely reassuring (protein binding changes)</td>
</tr>
<tr>
<td><strong>Women of childbearing potential</strong></td>
<td>Counsel all on teratogenicity; contraception counseling (enzyme inducers reduce OCP efficacy); preconception planning; folic acid; prefer lamotrigine, levetiracetam over valproate</td>
</tr>
<tr>
<td><strong>Elderly</strong></td>
<td>Increased sensitivity to ASM side effects; cognitive effects; falls; start low, go slow; drug interactions (polypharmacy); lamotrigine, levetiracetam, lacosamide generally well-tolerated; avoid phenobarbital, high-dose phenytoin</td>
</tr>
<tr>
<td><strong>Renal impairment</strong></td>
<td>Reduce doses of renally-cleared ASMs: levetiracetam, gabapentin, pregabalin, topiramate, lacosamide; phenytoin, carbamazepine, valproate less affected</td>
</tr>
<tr>
<td><strong>Hepatic impairment</strong></td>
<td>Reduce doses of hepatically-metabolized ASMs: phenytoin, carbamazepine, valproate, lamotrigine; levetiracetam, gabapentin safer</td>
</tr>
<tr>
<td><strong>Cardiac disease</strong></td>
<td>Avoid lacosamide if significant AV block (PR prolongation); carbamazepine has cardiac conduction effects; check ECG</td>
</tr>
<tr>
<td><strong>Psychiatric comorbidity</strong></td>
<td>Depression common in epilepsy; levetiracetam can cause behavioral side effects (irritability, aggression) — consider brivaracetam instead; valproate may worsen depression; lamotrigine has mood-stabilizing properties</td>
</tr>
</tbody>
</table>
<hr />
<p><em>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</em></p>












                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/blondarb/neuro-plans" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      
      <script id="__config" type="application/json">{"annotate": null, "base": "../..", "features": ["navigation.instant", "navigation.tracking", "navigation.sections", "navigation.expand", "navigation.top", "search.suggest", "search.highlight", "content.code.copy"], "search": "../../assets/javascripts/workers/search.2c215733.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.79ae519e.min.js"></script>
      
        <script src="../../assets/js/comments.js"></script>
      
    
  </body>
</html>